FDA application for first dispersible single tablet regimen containing dolutegravir (DTG) for children living with HIV.
If approved, this approval will result in further treatment options for younger children living with HIV.
Paediatric HIV remains a global issue, with children disproportionately affected by the HIV epidemic. Latest statistics show there are 1.7 million children living with HIV globally, with most AIDS-related deaths among this group occurring during the first five years of life.
Major obstacles persist for children, such as the availability of HIV testing, continued vertical transmission, slow initiation of treatment and, poor availability of optimised paediatric formulations of antiretrovirals (ARVs). The availability of age-appropriate treatment options is essential in ensuring children around the world can access optimal care.
115 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.